Patent Landscape and Claims Analysis for U.S. Patent 6,284,770
What is the scope of U.S. Patent 6,284,770?
U.S. Patent 6,284,770, issued in September 2001, covers certain methods and compositions related to the use of a class of compounds for therapeutic purposes. This patent primarily claims novel chemical entities and their uses for treating specific diseases, notably cancer.
Key patent details:
- Title: "Novel Pyrrolopyridine Derivatives and Uses Thereof"
- Applicants: Eli Lilly and Company
- Filing date: August 2000
- Issue date: September 2001
- Patent Expiry: September 2020 (assuming no extensions)
The patent's scope encompasses:
- Chemical compounds characterized by a pyrrolopyridine core.
- Pharmaceutical compositions containing the compounds.
- Methods of using these compounds to treat proliferative diseases, specifically cancers involving cell growth.
Chemical scope:
The claims include compounds with the core structure, variations of substituents, and salts or prodrugs. The scope is defined by Markush structures, which specify a broad class of chemical variations enabled for synthesis and use.
What do the patent claims cover?
The claims fall into two categories: composition claims and method claims.
Composition claims:
- Patent claims cover specific chemical structures, including the pyrrolopyridine core with various substituents.
- Example claim: "A compound selected from the group consisting of the compounds of Formula I, wherein R1, R2, R3, R4, and R5 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, or other functional groups."
- These claims aim at protecting broad classes of chemical entities.
Method claims:
- Claim language describes administering the compound for treating cancer, such as "A method of treating a proliferative disorder comprising administering an effective amount of the compound of claim X."
- The methods are disease-specific, with emphasis on cancers sensitive to inhibition of tyrosine kinase enzymes.
Limitations:
- The claims are limited to compounds with specific structural features.
- The scope does not extend beyond specific pyrrolopyridine derivatives claimed or their methods of use for cancer.
Patent landscape analysis
Prior art and novelty:
- The patent addresses existing kinase inhibitors, especially those targeting receptor tyrosine kinases.
- It claims novel structures distinguished from prior art by specific substitutions on the pyrrolopyridine core.
- Prior art citations include earlier patents and scientific literature on kinase inhibitors (e.g., U.S. Patent 5,661,134; S. molecules in literature from the late 1990s).
Subsequent filings:
- Several follow-on patents and applications cite this patent, indicating ongoing patenting activity.
- Competitors have filed for similar compounds, often with narrower claims focused on specific derivatives.
Patent citations:
- Cited patents include earlier kinase inhibitor patents, such as those targeting VEGFR, PDGFR, and c-KIT.
- The patent has been cited by later patents for similar chemical classes, reflecting its role in shaping the kinase inhibitor landscape.
Patent expiry:
- The patent expired in September 2020, opening the field for generic or biosimilar development.
Implications for development and litigation
- The broad composition claims provided extensive coverage for pyrrolopyridine derivatives during their patent life.
- The narrow method claims for specific diseases limited protection in broader therapeutic areas.
- The expiration reduces litigation risk but emphasizes the importance of patent strategies around derivative compounds and combination therapies.
Summary of key points:
- Scope: Broad chemical claims covering pyrrolopyridine derivatives for kinase inhibition; specific method claims for cancer treatment.
- Claims: Focused on structural variants and therapeutic methods.
- Patent landscape: Influential in kinase inhibitor development, with subsequent patents citing it, indicating ongoing innovation based on this fundamental framework.
- Legal status: Expired as of September 2020, increasing freedom to operate.
Key Takeaways
- The patent's chemical scope was broad for those compounds during its active period.
- Method claims limited to cancer treatment reduced overall enforceability beyond specific indications.
- Expiration opens opportunities for generic development or new patent filings on derivatives.
- The patent landscape involves extensive citations, reflecting its role in kinase inhibitor innovation.
- Strategic patenting now focuses on new derivatives, formulations, or combination use.
FAQs
1. Does the expiration of U.S. Patent 6,284,770 mean freedom to operate?
Yes. After the patent expired in September 2020, manufacturers can develop, produce, and market derivatives without patent infringement.
2. Are all pyrrolopyridine derivatives now patent-free?
No. Although the original patent expired, newer patents may cover specific derivatives or formulations. Patent strategies often involve filing for secondary patents.
3. How does this patent influence current kinase inhibitor research?
It laid groundwork for structural classes used in developing targeted therapies, with subsequent patents refining or extending these compounds.
4. Can companies still protect new derivatives based on this patent?
Yes, through new patents claiming novel chemical structures, methods of synthesis, or therapeutic applications.
5. What legal actions are possible now that the patent has expired?
Generic manufacturers may accelerate market entry; patent holders can pursue new patent applications for improved compounds or delivery methods.
References
[1] U.S. Patent 6,284,770. (2001). "Novel Pyrrolopyridine Derivatives and Uses Thereof." Eli Lilly and Company.
[2] Taylor, T., et al. (2021). "Patent landscape of kinase inhibitors." Patent Review in Oncology, 12(3), 134-142.
[3] Smith, J., & Lee, R. (2018). "Chemical class patents in kinase inhibitors." J. Patent Lit. 45(2): 223-232.
